Showing results (321-330 of 369) with videos related to

Sort By:
Pageof 37
Journal of the American College of Cardiology|August 30, 2022
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
JAMA Cardiology|May 20, 2023
Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER TrialAlexander Peikert, Alvin Chandra, Mikhail N Kosiborod, et al.
Circulation|March 6, 2023
Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER TrialToru Kondo, Karola S Jering, C Jan Willem Borleffs, et al.
Diabetes Care|December 11, 2025
Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized TrialJohannes F E Mann, Nikolaus Marx, John E Deanfield, et al.
European Heart Journal|November 20, 2024
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney diseaseJohn W Ostrominski, Mats C Højbjerg Lassen, Brian L Claggett, et al.
European Journal of Heart Failure|March 15, 2024
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVERAlexander Peikert, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|February 7, 2021
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HFLi Shen, Søren Lund Kristensen, Olof Bengtsson, et al.
JAMA Cardiology|November 3, 2022
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|September 2, 2022
Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HFCarly Adamson, Lorna M Cowan, Rudolf A de Boer, et al.
European Journal of Heart Failure|November 7, 2022
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartanMingming Yang, Jawad H Butt, Toru Kondo, et al.
Pageof 37